Genotype ECG Prediction

Bridging Genotype ECG Prediction to Enhanced Cardiovascular Risk Assessment

Genotype ECG prediction advancements, exemplified by the CapECG model, enable direct mapping of genetic data to electrocardiogram traits, overcoming UK Biobank limitations where only 10% of samples pair genotypes with ECGs. This attention-based Capsule Network predicts 169 ECG traits for 388,284 individuals lacking ECG data, boosting CVD risk prediction to an average AUC of 0.80 versus 0.71 from polygenic scores, and unlocks novel genetic insights.

CapECG’s Mapping Precision

CapECG delivers a mean Pearson correlation of 0.62 on 7,422 UKB test samples, robustly linking genotype to ECG morphology. Extending genotype ECG prediction to the full genotype-only cohort refines risk models for six CVDs, surpassing polygenic scores via features like spatial QRS-T angle (spQRSTa).

GWAS Power Surge

Imputed spQRSTa from genotype ECG prediction fuels a GWAS revealing 133 significant SNPs—33 matching a prior study on 118,780 people, exceeding the 13 from 29,692 observed cases—boosting discovery of new associations.

Capsule Network Architecture

Built on Python 3.9.16, PyTorch 1.12.1, and torch-geometric 2.3.1, CapECG uses attention mechanisms for dimensionality reduction. UKB data access follows official protocols; GWAS stats are on Zenodo, code at GitHub (biomed-AI/CapECG), with supporting tools like TwoSampleMR and trait extraction from referenced sources.

HEOR and Precision Medicine Impact

Genotype ECG prediction scales CVD assessment from routine genetic data, slashing ECG costs and amplifying biobank value. It elevates risk AUCs for better pricing of genetic tests and therapies, fueling targeted interventions amid precision medicine shifts.